Rêgo, Thaís de Salgado; da Silva Ash, Louise; Pessoa, Leticia; Barreto da Silva Feijó, Márcia; Leite, Juliana; de Sousa dos Santos, Aline; Soares da Costa, Carlos Alberto; Teles Boaventura, Gilson

The intake of Yam (Dioscorea bulbifera Linn) attenuated the hyperglycemia and the bone fragility in female diabetic rats

Grupo Aula Médica
Madrid, España

Available in: http://www.redalyc.org/articulo.oa?id=309231666018
The intake of Yam (Dioscorea bulbifera Linn) attenuated the hyperglycemia and the bone fragility in female diabetic rats

Thaís de Salgado Rêgo¹, Louise da Silva Ash¹, Leticia Pessoa¹, Márcia Barreto da Silva Feijó², Juliana Leite³, Aline de Sousa dos Santos³, Carlos Alberto Soares da Costa¹ and Gilson Teles Boaventura¹


Abstract

Introduction: Diabetic patients have a higher risk to osteoporotic fractures. Foods, such as yam, to oppose hyperglycemia, has been used to treatment of diabetes.

Objective: The goal was assess the role of Brazilian yam (Dioscorea bulbifera) on glycemia and bone parameters of female diabetic rats.

Methods: Female Wistar rats with 3 months age were allocated in three groups. Control group (C, n = 6), treated with normal fat diet. Diabetic rats treated with high-fat diet without (DM, n = 8) and with (DMY, n = 8) liophilized yam flour. After 5 weeks of the experiment, serum glucose and insulin, pancreas mass, number and area of pancreas islets were quantified. And femur parameters were analyzed by dual-energy X-ray absorptiometry (DXA) and computed tomography (CT).

Results: Differences were considered significant if P<0.05. Diabetic groups showed lower (P < 0.05); femur and pancreas mass, area of the pancreatic islets and insulin. However, DMY showed lower (-10%, P < 0.05) concentrations of glucose to DM group. Femur, by DXA, showed lower bone mineral density, content and area in the DM group. While the DMY group showed greater (+27%, P < 0.05) radiodensity of femoral head when compared to DM group.

Discussion: Brazilian yam flour supplement did not fix a defect, but alleviated the consequences of the experimental diabetic disease. It showed results to control the rise in blood glucose levels in diabetic rats, suggesting protection in oxidative agents and postpone harm in the bone.

Conclusion: Considering all the findings of the present study, our results suggest that yam flour does act producing benefits in the experimental diabetes.

DOI:10.3305/nh.2014.29.2.7046

Key words: Yam. Dioscorea bulbifera. Diabetes. Femur. Wistar.

Correspondence: Thaís de Salgado Rêgo.
Experimental Nutrition Laboratory.
College of Nutrition. Federal Fluminense University.
Rua Mário Santos Braga. 30.
E-mail: thais.nutricionista@ymail.com


370
Abbreviations

AIN: American Institute of Nutrition.
BMC: Bone Mineral Content.
BMD: Bone Mineral Density.
C: Control rats group.
CT: Computed Tomography.
DM: Diabetic rats group.
DMY: Diabetic rats group given yam flour.
DXA: Dual-energy X-ray absorptiometry.
HFD: High Fat Diet.
HU: Hounsfield Unit.
ND: Normal Diet.
STZ: streptozotocin.
UFF: Federal Fluminense University.
WHO: World Health Organization.

Introduction

There is a global epidemic of diabetes mellitus, and the number of affected is expected to rise more than 430 million by 2030. The widespread chronic disorder of diabetes adversely affects multiple organ systems including bones, a highly dynamic tissue that undergoes constant remodeling. Besides, a worldwide prevalence of osteoporosis is estimated to be greater than 200 million people, with the majority being women.

Herbal medicine is the oldest form of health care known to humanity. The use of plants and plant foods to oppose hyperglycemia has been practiced by herbalists for a long time. The World Health Organization (WHO) expert committee has recommended that plants possessing hypoglycemic activity may provide a utilizable source of new oral antidiabetic drug, or may act as simple dietary adjuncts to the existing therapies.

The genus Dioscorea has been used widely in traditional Chinese medicine to promote human health. The Pharmacopoeia of the People’s Republic of China describes its employing for the treatment of several diseases including diabetes.

The physico-chemical properties and phytochemical investigations of starch foods compounds have been studied, but little attention has been given to the tubers of Dioscoreaceae, especially in Brazil, where current studies and investigations on yams are incipient. Thriving well in tropical and subtropical environmental conditions, varied yam species are satisfactorily developed in the Brazilian ecosystems, especially in the Northeast, but it still is an underutilized crop. The unknown diversity and features of Dioscorea in Brazil, is information blank and needs to be filled in to reinforce how important is the yam as a healthy food source.

One of the serious skeletal complications in bones is osteoporotic fractures due weakened bone strength. Both type I and 2 diabetic patients have a higher risk of sustaining osteoporotic fractures compared to non-diabetic patients. In order to realize the health benefits which can be obtained from yam, additional research on its effects in bone health are required. Thus, here we intend to show if yam added in a diabetic rats diet would influence the glycemia and bone parameters altered by the disease.

Materials and methods

Plant Material

Tubers of yam (Dioscorea bulbifera) were purchased from a local market in Belo Horizonte (MG, Brazil) and categorized by a biologist in comparison to the existing voucher specimens in Jardim Botânico (RJ, Brazil): Couto, R.S. 164. Each tuber sample was washed free of dirt, skinned, cut (0.5-cm thick slices), boiled (60 seconds), freeze-dried and lyophilized. The dried yam was milled, passed through a 35-mesh sieve and stored in plastic bags at −20 °C until use. The lyophilized yam powder contains (g/100 g): Moisture 3.62; ash 2.85; protein 7.33; fat 0.38; carbohydrates (starch + reducing sugar) 82.13.

Animals

The studied was conducted in Female albino Wistar rats with 3 months age, weighting about 190-200 g. The animals maintained under controlled room temperature (22 ± 2 °C) with 12 h light/12 h dark cycle. All the rats were fed a normal chow diet (Nuvital®, Nuvilab, PR, Brazil) and water ad libitum, prior to the dietary manipulation. All procedures were approved by the Animal Ethics Committee of the UFF (n 37, 2010).

Induction of experimental diabetes

The rats were allocated into two dietary regimens by feeding either Normal Diet (ND: 10% lipids, 12% protein and 78% de carbohydrate as a percentage of total kcal), according to American Institute of Nutrition (AIN) recommendations, or High Fat Diet (HFD: 60% lipids, 14% protein and 26% de carbohydrate as a percentage of total kcal) ad libitum, for 3 weeks. The diets composition and preparation were described. Then, the HFD rats were injected intraperitoneally (i.p.) with streptozotocin (STZ, 35mg/kg), while the respective control rats were given vehicle citrate buffer (1ml/kg, i.p, pH 4.4). After 1 week, the fasting glucose level of a blood obtained from the tail, was measured using a glucometer and the rats with the glycemia of more than 290 mg/dl were considered diabetic and selected for the study.

Experimental design

The rats were divided into three groups based on diet (table I): Control group (C: Six healthy rats) received an AIN-93M-based control diet; Diabetic group (DM: Eight diabetic rats) received a 45% fat (of total kcal) diet; Diabetic Yam group (DMY: Eight diabetic rats),
treated with diet containing 25% of yam flour. The animals were given ad libitum access to their respective diets and water. During the 5 weeks of experiment, body weight change and total food intake were evaluated twice a week. At the end of this period the animals, after 6-hours fasting, were anesthetized by Thiopen-tax® followed by exsanguination. Blood samples was collected by cardiac puncture for serum separation and stored at -20°C for biochemical analysis. Pancreas and left femur were removed, rinsed, and weighed.

**Serum analysis**

Glucose analysis was assayed by colorimetric method (Bioclin/Quibasa, Belo Horizonte, MG, Brazil). Serum insulin concentrations were measured using multiplex assay kits (RADPK-81K).

**Pancreas morphology**

Samples of pancreas were fixed in buffered formalde-hyde and processed following the routine technique by paraffin inclusion. Serial areas of pancreatic islets (µm²) were determined (fig. 1). Digital images of 20 islets in pancreas sections were acquired at random with an Optronics CCD video camera system and Olympus BX40 light microscope and analyzed using the software IMAGE J (NIH, USA).

**Bone analyses**

The left femur was cleaned of soft tissue, weighted and kept at -80°C until analysis. To measure the Bone Mineral Density (BMD), Bone Mineral Content (BMC) and bone area by dual-energy X-ray absorptiometry scan (DXA. Lunar, Wisconsin, USA) with specific software (encore 2008. Version 12.20 GE Healthcare). The DXA results were obtained using a previously described procedure13. In order to mimic soft tissue conditions, excised bones were fixed on constant volume of rice in a plastic container. The radiodensity of femoral head (fig. 2) was obtained by scan computed tomography (CT. Helicoidal model HISPEED, GE®) measured with a computerized analyzer software system (eFilm Lite, 2.0, 2003, Milwaukee, USA) by manual measurement Toll-Ellipse. The DXA and CT technicians did not know about the experimental protocol.

**Statistical analyses**

Statistical analysis were carried out using the Graph Pad Prism statistical package version 5.00, 2007 (San Diego, CA, USA) using one-way ANOVA, followed by Newman-Keuls post-test. All results are expressed as Means ± SEM with significance level of 0.05.

**Results**

During the nutritional period, the DM groups showed similar food intake, but these were significantly increased (+64%) compared to the control group. In regard to the body mass, at the end of the experimental period, the DM groups showed lower (P < 0.05) values to the control group (table II). When compared to control group, the DM (-42%) and DMY (-31%) showed lower (P < 0.05) pancreas mass. The experimental groups showed lower serum concen-

<table>
<thead>
<tr>
<th>Ingredient (g/100 g)</th>
<th>C</th>
<th>DM</th>
<th>DMY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>12.76</td>
<td>12.77</td>
<td>12.77</td>
</tr>
<tr>
<td>Cornstarch</td>
<td>63.31</td>
<td>45.79</td>
<td>20.79</td>
</tr>
<tr>
<td>Yam Flour</td>
<td>–</td>
<td>–</td>
<td>25.0</td>
</tr>
<tr>
<td>Sucrose</td>
<td>10.0</td>
<td>10.0</td>
<td>10.0</td>
</tr>
<tr>
<td>Soybean oil</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Lard</td>
<td>–</td>
<td>17.51</td>
<td>17.51</td>
</tr>
<tr>
<td>Fiber</td>
<td>5.0</td>
<td>5.0</td>
<td>5.0</td>
</tr>
<tr>
<td>AIN-93M Mineral Mix</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
</tr>
<tr>
<td>AIN-93 Vitamin Mix</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>L-Cystine</td>
<td>0.18</td>
<td>0.18</td>
<td>0.18</td>
</tr>
<tr>
<td>Choline Bitartrate</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Energy, kcal/g</td>
<td>3.46</td>
<td>4.45</td>
<td>4.53</td>
</tr>
<tr>
<td>Protein (% of energy)</td>
<td>12.00</td>
<td>12.00</td>
<td>13.80</td>
</tr>
<tr>
<td>Carbohydrate (% of energy)</td>
<td>63.39</td>
<td>49.32</td>
<td>49.78</td>
</tr>
<tr>
<td>Fat (% of energy)</td>
<td>5.01</td>
<td>22.30</td>
<td>22.11</td>
</tr>
</tbody>
</table>

Table I

*Composition of experimental diets*

Formulated to meet the American Institute of Nutrition AIN-93G recommendations for rodent diets6, 15. C: Control group, fed a control diet; DM: Diabetic group fed high fat diet; DMY: Diabetic group fed high fat diet containing yam flour. Casein: Farmos®; Cornstarch: Unilever Bestfoods®; Sucrose: União®; Soybean oil: Cargill®; Lard: Sadia®; Fiber: Blanver®; Mineral and Vitamin Mix: PragSoluções®; L-Cystine and Choline Bitartrate: M. Cassab®.
trations of insulin and high concentrations of glucose \( (P < 0.05) \), respectively. However, the DMY group showed lower concentrations of glucose (-10\%, \( P < 0.05 \)) when compared to the DM group. Morphometric analyses showed lower (-57\%, \( P < 0.05 \)) pancreatic islet area in DM and DMY groups in relation to C group (table II).

Bone analyses showed that lower \( (P < 0.05) \) femur mass were observed in the DM (-17\%) and DMY (-9\%) in regard to control group. Evaluating the femur using DXA showed that the bone area in the DM was lower when compared to the others groups. In the same way, the DM group showed lower \( (P < 0.05) \) BMC in regard to control and DMY groups (-19\% and -7.5\%, respectively). BMD was lower \( (P < 0.05) \) in the experimental groups. However, the percentage difference was -11\% and -5.8\% in DM and DMY, respectively, when compared to control group. The CT analysis showed lower \( (P < 0.05) \) radiodensity of femoral head in DM and DMY groups (-37\% and -20\%, respectively). Simultaneously, the DMY group was greater radiodensity (+27\%, \( P<0.05) \) than the DM group when comparing the experimental groups (table III).

Discussion

A new diet health paradigm is evolving which places more emphasis on the positive aspects of diet\textsuperscript{14}. The Plant Kingdom constitutes the main source of many of our major current therapeutic drugs and it is also the basis of folk medicine and phytotherapy. A wide variety of natural compounds with therapeutic effects on diabetes\textsuperscript{15} and on bone parameters have been reported\textsuperscript{16}. Bone status is closely linked to regulation of energy metabolism and insulin sensitivity and it should be considered as a vital target for therapies which modulate energy metabolism\textsuperscript{17}. Yam, seems to act in both condition, Yin\textsuperscript{18} related that among 30 traditional Chinese herbs, yam (Dioscorea spongiosa) showed the strongest activity of the stimulation on bone formation with a rate of 67\% and He\textsuperscript{19} suggests that yam (Dioscorea opposita) may exert a beneficial action on both diabetes and diabetic complications. The results of the present study corroborate the healthy effects of yam (Dioscorea bulbifera) flour on bone fragility observed in diabetic context.

Since the combination of high fat diet (HFD)-fed and low-dose streptozotocin (STZ)-treated rat which serves as an alternative animal model for type 2 diabetes has been proved to be suitable for testing antidiabetic agents\textsuperscript{12}, we used this model in this study. Indeed,
after performing the protocol our diabetic animals showed similar glycemia (over 290 mg/dl) (data not shown), however there was a decrease in body mass and an impairment in insulin secretion. Somehow our animals resembled to type 1 diabetes.

Hyperglycemia, the most important feature of diabetes mellitus, is in itself very dangerous for diabetic patients. The diabetes characteristics of body mass losses and increased food intake due metabolic changes attributed by the lack or deficiency of insulin, were presents in our diabetic rats and were affected by the nutritional intervention. Our results showed that, despite it was not similar to control group, yam flour increased insulin levels of diabetic rats, but it decreased the fasting blood glucose. The lower pancreas mass, islets number and area results provide the histological evidence of severe pancreatic damage in conjunction with the blood biochemical results. All these results suggest that the improvement of glycemic control may be not by the increasing of insulin release. Many pathways has been studied: a possible insulin-like action, an insulin sensitizing action at tissue level, an increased GLUT-4 gene expression via insulin independent mechanisms and an impairment of glucose translocation by decreased in Na+–K+–ATPase activity has been suggested and assigned to yam.

The bone turnover and thus the skeletal integrity may also be affected by diabetes, which can represent a hitherto overlooked complication of diabetes. Yam flour seems to ameliorate bone parameters weakened by the disease. The decrease of BMD is already expected by diabetes, seems to be due poor glycemic control and loss of bone anabolic action (due lack of insulin). BMD may increase with BMC, and BMD decreases with increasing bone areal size. Our results did not differ on bone mineral density in diabetic groups, but the decrease of bone mineral content present only in DM group, indicates that yam flour is able to delay the BMC losses or an anabolic action improving osteoblastogenesis. A possible insulin-like action brought up already can underline the yam action on either glycemic control observed in our results and on proliferation and bone mineralization suggested by Yin et al.

DXA is an important clinical tool because of its availability and low levels of radiation exposure, and the diagnostic criteria for DXA established by WHO in 1994 have long been used as the gold standard in the clinical diagnosis of osteoporosis. However it is unclear whether the DXA-based measures of bone geometry provide important information in addition to a BMD with respect to bone adaptations to mechanical loading. Computed tomography allows measurement of volumetric trabecular bone density without superimposition of cortical bone and other tissue and the com-

<table>
<thead>
<tr>
<th>Table II</th>
<th>Food intake, body mass and pancreatic morphometry at the end of the experimental period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C (n6)</td>
</tr>
<tr>
<td>Daily food intake (g)</td>
<td>14.88 ± 1.05a</td>
</tr>
<tr>
<td>Body mass (g)</td>
<td>302.80 ± 15.55a</td>
</tr>
<tr>
<td>Pancreas (g)</td>
<td>3.85 ± 0.50a</td>
</tr>
<tr>
<td>Glycemia (mg/dL)</td>
<td>183.70 ± 6.31a</td>
</tr>
<tr>
<td>Insulin (µUI/ml)</td>
<td>81.56 ± 10.10a</td>
</tr>
<tr>
<td>Area of the pancreatic islets (µm²)</td>
<td>6474 ± 1351a</td>
</tr>
</tbody>
</table>

C: Control group, fed a control diet; DM: Diabetic group fed high fat diet; DMY: Diabetic group fed high fat diet containing yam flour. Mean values within a row with dissimilar superscripts (a, b and c) are significantly different (one-way ANOVA, P < 0.05).

<table>
<thead>
<tr>
<th>Table III</th>
<th>Femur parameters at the end of the experimental period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
</tr>
<tr>
<td>Mass (g)</td>
<td>0.75 ± 0.01a</td>
</tr>
<tr>
<td>Bone area (cm²)</td>
<td>2.33 ± 0.21</td>
</tr>
<tr>
<td>BMC (g)</td>
<td>0.46 ± 0.02a</td>
</tr>
<tr>
<td>BMD (g/cm²)</td>
<td>0.17 ± 0.01a</td>
</tr>
<tr>
<td>Femoral head (Hu)</td>
<td>975.20 ± 50.66a</td>
</tr>
</tbody>
</table>

C: Control group, fed a control diet; DM: Diabetic group fed high fat diet; DMY: Diabetic group fed high fat diet containing yam flour. Mean values within a row with dissimilar superscripts (a, b and c) are significantly different (one-way ANOVA, P < 0.05).
partmental bone tissue adaptations that result from mechanical (un)loading. CT has a greater diagnostic sensitivity than DXA, and it showed an impairment in radiodensity of diabetic rats and yam flour present in diet of diabetic rats brought the radiodensity to similar values of control animals, as a result of an improvement of bone quality. The influences of yam ameliorating bone parameters was related with antosteoprotic activity; improving plasma levels of calcium and mineral density of the femur and lumbar vertebrae; positive effects in proliferation assay in osteoblastic cells; inhibition of osteoclasts and stimulate bone mineralization and proliferation.

In conclusion, our experiment with Brazilian yam (*Dioscorea bulbifera*) flour supplement did not fix a defect, but alleviated the consequences of the experimental diabetic disease. It showed results to control the rise in blood glucose levels in diabetic rats, suggesting protection in oxidative agents and postpone harm in the bone. Considering all the findings of the present study, our results suggest that yam flour does act producing benefits in the experimental diabetes.

References